Volume 70 Number 3 May 2003	back to contents

Address correspondence to Steven Fruchtman, M.D., Clinical Associate Professor of Medicine, Hematology, Box 1410, Mount Sinai School of Medicine, One East 100th Street, New York, NY 10029.

Presented at the Issues in Medical Ethics 1999 Conference at the Mount Sinai School of Medicine, New York, NY on December 10, 1999, and updated as of December 30, 2002.

ABSTRACT

Historically, a variety of hematological disorders of the bone marrow, such as acute leukemia, chronic myelocytic leukemia and severe aplastic anemia, were invariably fatal. In the past two decades, basic and clinical scientists have been able to change this grim reality into a more hopeful outcome by replacing the diseased bone marrow with stem cells from either a family donor or an unrelated volunteer donor with identical human leukocyte antigens (HLA). Because of progress in this field, the initial experience of mainly using sibling donors has now been expanded to the use of either unrelated adult donors or cord blood cells as a source of hematopoietic cells. These approaches have created ethical concerns for donors and families, concerns that need to be discussed and understood by patients, volunteer donors and health care professionals.

KEY WORDS

Transplant, stem cell, stem cell transplant, ethics.

MSSM Home

Back Issues | Indexes | Search | Journal Home